View of MACRO-COSTING OF THE USE OF BORTEZOMIB IN THE TREATMENT OF MULTIPLE MYELOMA FROM THE PERSPECTIVE OF THE SUS | JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA